Vital Innovations Holdings Ltd. (6133) AI Stock Analysis

• Market Cap: HK$208.25M
• Dividend Yield: N/A
• Average Volume (3M): 54.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.15
• Revenue Growth: 3.70%
• EPS Growth: 5.90%
• Country: HK
• Employees: 24
• Sector: Technology
• Sector Strength: 88
• Industry: Consumer Electronics
• EPS (TTM): -0.01
• Shares Outstanding: 850,000,000
• 10 Day Avg. Volume: 11,000
• 30 Day Avg. Volume: 54,300
• PEG Ratio: -7.17
• Price to Book (P/B): 0.25
• Price to Sales (P/S): 0.12
• P/FCF Ratio: -11.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

Vital Innovations Holdings Ltd. is facing significant financial challenges, with persistent net losses and negative margins impacting its overall score. Technical analysis shows some short-term bullish momentum, but valuation metrics are poor due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Vital Innovations Holdings Ltd. Business Overview & Revenue Model

Company Description

Vital Innovations Holdings Ltd. (6133) is a diversified holding company focused on investing in and nurturing innovative technology and health-related enterprises. The company operates across various sectors, including biotechnology, health technology, and sustainable innovations. Its core offerings include the development of cutting-edge medical devices, telehealth solutions, and wellness products aimed at enhancing the quality of life and promoting health equity.

How the Company Makes Money

Vital Innovations Holdings Ltd. generates revenue through multiple streams, primarily by investing in early-stage companies within its sectors and taking equity stakes in these businesses. The company monetizes its investments through capital gains as these companies grow and either get acquired or go public. Additionally, Vital Innovations earns income from licensing agreements for its proprietary technologies and products developed in-house. Strategic partnerships with healthcare providers, research institutions, and technology firms further bolster its revenue, allowing for collaborative projects that drive innovation and market penetration. The company also benefits from government grants and funding aimed at fostering advancements in health technology.

Vital Innovations Holdings Ltd. Financial Statement Overview

Summary

Vital Innovations Holdings Ltd. faces significant profitability challenges with persistent net losses and negative margins. While the balance sheet is stable with low leverage, the lack of profitability impacts return metrics negatively. Cash flow management shows some improvements, but the company struggles to generate positive operating cash flows.

Income Statement

Vital Innovations Holdings Ltd. has shown a fluctuating revenue trend, with a recent increase in revenue but continued negative profitability. The gross profit margin remains weak, and net profit margins are negative, indicating ongoing operational challenges. EBIT and EBITDA margins are also negative, reflecting the company's struggle to cover operating costs effectively.

Balance Sheet

The company's balance sheet shows a relatively stable equity position, with a low debt-to-equity ratio indicating minimal leverage risk. However, the return on equity is negative due to consistent net losses. The equity ratio remains strong, suggesting a solid equity base compared to total assets.

Cash Flow

Cash flow analysis reveals volatile operating cash flows, with recent improvements in free cash flow indicating better cash management. However, the operating cash flow remains negative, and the cash flow ratios indicate challenges in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	792.56M	1.06B	835.61M	1.09B	672.65M	881.14M
Gross Profit	4.76M	5.95M	3.01M	4.70M	-486.00K	-79.57M
EBITDA	-13.58M	-18.02M	-18.12M	-15.44M	-19.07M	-95.42M
Net Income	-15.89M	-21.00M	-20.84M	-17.46M	-20.50M	-97.63M
Balance Sheet
Total Assets	598.59M	614.60M	628.86M	620.41M	640.56M	710.60M
Cash, Cash Equivalents and Short-Term Investments	7.83M	8.20M	24.35M	37.58M	26.65M	54.37M
Total Debt	24.89M	30.63M	34.00M	9.00M	15.37M	21.12M
Total Liabilities	124.69M	132.28M	125.61M	96.32M	98.91M	148.38M
Stockholders Equity	473.89M	482.31M	503.31M	524.15M	541.70M	562.20M
Cash Flow
Free Cash Flow	-6.10M	-11.05M	-40.50M	15.46M	-19.72M	3.91M
Operating Cash Flow	-6.10M	-11.05M	-40.49M	15.46M	-19.72M	3.91M
Investing Cash Flow	3.60M	3.59M	-58.00K	-219.00K	137.00K	12.00K
Financing Cash Flow	-1.76M	-8.68M	26.85M	-7.05M	-9.08M	-758.00K

Vital Innovations Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.25
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6133, the sentiment is Positive. The current price of 0.25 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.24, and above the 200-day MA of 0.23, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.68 is Neutral, neither overbought nor oversold. The STOCH value of 69.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6133.

Vital Innovations Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0912	―	HK$367.38M	10.68	4.39%	9.30%	-0.88%	7.28%
Sector *	―	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
1747	―	HK$2.30B	68.07	15.73%	0.34%	11.29%	40.42%
0927	―	€293.83M	16.80	-6.99%	10.00%	-6.75%	-310.42%
6133	―	HK$208.25M	―	-4.14%	―	3.70%	5.90%
8005	―	HK$211.45M	―	-8.93%	―	-59.19%	-159.11%
2369	―	$467.70M	-2.06	-13.04%	―	8.62%	-24.87%

Vital Innovations Holdings Ltd. Corporate Events

Vital Innovations Reports Interim Financial Results with Reduced Losses

Vital Innovations Holdings Ltd. reported its unaudited interim results for the six months ending June 30, 2025, showing a decrease in revenue and gross profit compared to the same period in 2024. The company experienced a net loss of RMB 8,419,000, slightly improved from the previous year’s loss, indicating ongoing financial challenges but a slight reduction in losses, which may impact its market positioning and stakeholder confidence.

The most recent analyst rating on (HK:6133) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Vital Innovations Holdings Ltd. stock, see the HK:6133 Stock Forecast page.

Vital Innovations Schedules Board Meeting for Interim Results

Vital Innovations Holdings Ltd. has announced a board meeting scheduled for August 27, 2025, to approve the interim results for the first half of 2025 and consider an interim dividend. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.